Literature DB >> 18835361

DNA methylation, epimutations and cancer predisposition.

Alexander Dobrovic1, Lasse S Kristensen.   

Abstract

Hereditary cancer syndromes caused by germline mutations give rise to distinct spectra of cancers with characteristic clinico-pathological features. Many of these hereditary cancer genes are silenced by methylation in a similar spectrum of sporadic cancers. It is likely that the initiating event in some of those cases of sporadic cancer is the somatic epigenetic inactivation (epimutation) of the same hereditary cancer gene. Recently, it has been shown that epimutations of certain hereditary cancer genes can be constitutional i.e. present throughout the soma. These epimutations may be inherited or arise very early in the germline. The heritability of these epimutations is very low as in most cases they are erased by passage through the germline. In other cases, predisposition to epimutations rather than the epimutations themselves can be inherited. These cases are characterised by Mendelian inheritance and are likely to be associated with sequence variants. Other sequence variants and environmental influences may also affect methylation propensity at a global level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835361     DOI: 10.1016/j.biocel.2008.09.006

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  25 in total

Review 1.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.

Authors:  Ee Ming Wong; Melissa C Southey; Stephen B Fox; Melissa A Brown; James G Dowty; Mark A Jenkins; Graham G Giles; John L Hopper; Alexander Dobrovic
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

Review 3.  Dark matters in AMD genetics: epigenetics and stochasticity.

Authors:  Leonard M Hjelmeland
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-01       Impact factor: 4.799

4.  Promoter methylation of candidate genes associated with familial testicular cancer.

Authors:  Lisa Mirabello; Christian P Kratz; Sharon A Savage; Mark H Greene
Journal:  Int J Mol Epidemiol Genet       Date:  2012-08-31

Review 5.  Early developmental conditioning of later health and disease: physiology or pathophysiology?

Authors:  M A Hanson; P D Gluckman
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 6.  Coordinated chromatin control: structural and functional linkage of DNA and histone methylation.

Authors:  Xiaodong Cheng; Robert M Blumenthal
Journal:  Biochemistry       Date:  2010-04-13       Impact factor: 3.162

7.  Analysis of mismatch repair gene mutations in Turkish HNPCC patients.

Authors:  Berrin Tunca; Monica Pedroni; Gulsah Cecener; Unal Egeli; Enrica Borsi; Abdullah Zorluoglu; Carmela Di Gregorio; Tuncay Yilmazlar; Omer Yerci; Maurizio Ponz de Leon
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

8.  LINE-1 methylation is inherited in familial testicular cancer kindreds.

Authors:  Lisa Mirabello; Sharon A Savage; Larissa Korde; Shahinaz M Gadalla; Mark H Greene
Journal:  BMC Med Genet       Date:  2010-05-17       Impact factor: 2.103

9.  The 46359CT polymorphism of DNMT3B is associated with the risk of cervical cancer.

Authors:  Daniel Hernández-Sotelo; Rubén García-Aguilar; Yaneth Castro-Coronel; Jonathan J Magaña; Marco Antonio Leyva-Vazquez; Luz del Carmen Alarcón-Romero; Esther López-Bayghen; Berenice Illades-Aguiar
Journal:  Mol Biol Rep       Date:  2013-05-16       Impact factor: 2.316

Review 10.  DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging.

Authors:  Kyong-chol Kim; Simonetta Friso; Sang-Woon Choi
Journal:  J Nutr Biochem       Date:  2009-09-04       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.